The price of DTC TV ad reviews
Executive Summary
FDA is charging pharmaceutical companies $41,390 to review a direct-to-consumer television ad during fiscal year 2008. The fees are based on company commitments to submit 151 ads for review and the need to generate $6.25 million to pay for FDA review activities and set up an operating reserve fund. The FDA Amendments Act, which establishes the voluntary DTC user fee program, requires collection of the fees within 120 days of the law's Sept. 27 enactment (1"The Pink Sheet" Nov. 26, 2007, p. 5). FDA is writing guidance on submission contents, format and procedures, but has given no date for its release...
You may also be interested in...
FDA Begins Reviewing DTC Ads As User Fee Program Faces Pay Or Die Deadline
Industry already has submitted 12 direct-to-consumer television ads to FDA for pre-review through the new DTC user fee program
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.